Biogen's patent

The latest casualty in the ongoing patent and marketing dispute between Biogen Inc. and Schering AG came last week in the revocation by the European Patent Office (EPO) of BGEN's so-called "Fiers patent" covering production

Read the full 355 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE